01—Abstract
Summary
Summary of the 8-K filed February 23, 2026. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific (BSX) filed an 8-K on February 23, 2026 reporting three developments: board expansion, a new share repurchase authorization, and the appointment of two new directors.
On February 18, 2026, the Board increased its size from ten to twelve and appointed Catherine (Cathy) Smith and Christophe Weber as directors, effective that date. Smith, the CFO of Starbucks, joins the Audit and Nominating and Governance Committees. Weber, president and CEO of Takeda Pharmaceutical until his planned retirement in June 2026, joins the Executive Compensation and Human Resources Committee and the Risk, Science and Technology Committee.
Both receive prorated standard non-employee director compensation through the 2026 annual meeting. The Board also approved an additional $4.0 billiona increase to the company's stock repurchase program, bringing total authorized repurchases to $5.0 billion. The filing states that the full amount remains available as of the filing date.
This is a substantial capacity expansion that signals management and the Board's confidence in capital deployment and provides flexibility for opportunistic buybacks. The board refresh follows the previously announced retirements of directors John Sununu and Yoshiaki Fujimori, who will not stand for re-election at the 2026 annual meeting.
The additions bring finance and strategy depth (Smith) and global pharmaceutical leadership (Weber) to the Board. For investors, the changes are governance-positive and largely non-financial in direct impact, while the repurchase expansion is the most material item for shareholder returns.
02—Key points
Key Highlights
- Board expanded from ten to twelve directors; Catherine R. Smith and Christophe P. Weber appointed effective February 18, 2026, with committee assignments effective February 23, 2026.
- Share repurchase authorization increased by $4.0 billion, bringing total available capacity to $5.0 billion, all of which remained available as of the filing date.
- Cathy Smith brings CFO experience from Starbucks, Nordstrom, Target, Walmart, Express Scripts and Bright Health, and serves on the PPG Industries board.
- Christophe Weber, CEO of Takeda Pharmaceutical since 2015, brings global pharmaceutical leadership and is set to retire from Takeda in June 2026.
- Board refresh follows the planned departures of John Sununu and Yoshiaki Fujimori, who will not stand for re-election at the 2026 annual meeting.
- New directors receive prorated standard non-employee director compensation (about $24,663 cash retainer and $42,420 equity award each), a modest immediate cost.
- Both new directors have no undisclosed arrangements with other persons and no material related-party transactions requiring disclosure under Item 404(a).
03—Questions
Frequently Asked Questions
How large is the new share repurchase authorization, and what does it mean for shareholders?
The Board approved a $4.0 billion increase to the existing $1.0 billion authorization, for a total of up to $5.0 billion in common stock repurchases. The full amount remained available as of the filing date. This gives management significant flexibility to return capital to shareholders, though the filing does not state a timeline or pace for purchases.
Why did Boston Scientific expand its board, and who are the new directors?
The Board increased its size from ten to twelve on the recommendation of the Nominating and Governance Committee. Catherine (Cathy) Smith, CFO of Starbucks, and Christophe Weber, CEO of Takeda Pharmaceutical until his June 2026 retirement, were appointed. The company framed the additions as bringing financial, strategic, and global pharmaceutical leadership experience, following the planned departures of directors John Sununu and Yoshiaki Fujimori.
Do the new directors receive special compensation or have conflicts of interest?
No special compensation was disclosed. Both directors receive standard non-employee director pay, prorated through the 2026 annual meeting: a cash retainer of about $24,663 and an equity award valued at about $42,420, with the share count set on March 2, 2026. The filing also states neither director has a material interest in any related-party transaction requiring disclosure under Item 404(a).
What committee roles will the new directors fill?
Cathy Smith joins the Audit Committee and the Nominating and Governance Committee, which leverages her financial expertise. Christophe Weber joins the Executive Compensation and Human Resources Committee and the Risk, Science and Technology Committee, which aligns with his pharmaceutical industry background. Both assignments became effective February 23, 2026.
04—Continue